Mibefradil is a novel Ca2+ antagonist acting on both L-and T-type Ca2+ channels, with a ten-
fold selectivity for T-type Ca2+ channels. It belongs to a chemical class different from other …

Properties of mibefradil Mibefradil is a novel calcium chan-nel antagonist with structural and
pharmacological characteristics clearly distinct from those of classical calcium antagonists. It …

Calcium antagonists are an established therapy for patients with hypertension and angina
pectoris, but their current usage is often limited by their pharmacologic profiles and side …

OBJECTIVE: To describe the pharmacology, pharmacokinetics, and clinical efficacy of
mibefradil compared with other agents used for hypertension and angina. DATA SOURCES …

Mibefradil is a recently introduced calcium antagonist that, as a tetralol derivative, is
chemically distinct from previous calcium antagonists. This article will review pertinent …

Mibefradil is the prototype of a new class of calcium antagonists that selectively block T‐type
voltage‐gated plasma membrane calcium channels in vascular smooth muscle. The drug is …

The voltage gated calcium channel family is a major target for a range of therapeutic drugs.
Mibefradil (Ro 40–5967) belongs to a new chemical class of these molecules which differs …

Mibefradil is a novel Ca2+ antagonist which blocks both high‐voltage activated and low
voltage‐activated Ca2+ channels. Although L‐type Ca2+ channel block was demonstrated …

Mibefradil is the first of a new class of calcium antagonists (CAs), the tetralol derivatives, that
selectively blocks the T-type calcium channel. The anti-anginal and anti-ischemic efficacy of …

ABSTRACT NNC 55‐0396 is a structural analog of mibefradil (Ro 40‐5967) that inhibits
both T‐type and high‐voltage‐activated (HVA) Ca2+ channels with a higher selectivity for T …